Skip to NavigationSkip to content

Perrigo appoints FDA director as regulatory head

Published on: 23/09/13

OTC healthcare products firm Perrigo Company has appointed the FDA’s Keith Webber to be its head of Regulatory Review.

The new role will have responsibility for advancing the approval of the firm’s Consumer Healthcare (CHC) and Prescription Pharmaceutical (Rx) regulatory applications pending with the FDA.

Providing guidance on scientific and regulatory strategy for new CHC and Rx pipeline products under development, Perrigo says he’ll be continuously advancing the quality of new regulatory applications. 

Webber served as acting director of the Office of the FDA's Pharmaceutical Science in the Center for Drug Evaluation and Research (CDER), which regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs.

Prior to that, he served as director of Office of Generic Drug (OGD), where he directed FDA regulation of generic pharmaceuticals including, legal, chemistry, bioequivalence, microbiology, clinical and labeling.

Perrigo's chairman, president and chief executive Joseph Papa said: "I am excited to welcome Keith to the Perrigo family. He brings to us a wealth of strategic, scientific and regulatory experience from his years working with the FDA. Keith will work closely with regulatory leadership to support new product selection and develop strategies and processes to achieve high quality applications and timely approvals, enabling us to bring quality, affordable products to the market."

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches